Abstract
Besides the many recognised compounds described and detailed in the present issue including the Vinca alkaloids, the taxanes, certain cryptophycines, epothilones and eleutherobines, several new products interacting with tubulin are identified regularly in the literature. These products may have been isolated from natural sources (plants, marine organisms, bacteria), but also more recently combinatorial, or at least automatised chemistry, has provided new families of small molecules, which on occasions have been found by High Throughput Screening directed against tubulin as a specific target. A recent review has listed more than one hundred of such derivatives [1]. Certain of these are in an advanced stage of pharmaceutical development, as reviewed by Li et al. [2] and von Angerer [3]. From a mechanistic point of view, these newer products may be classified into one of three main families, although exceptions to this rule are now also being reported on. microtubule stabilising compounds, Vinca alkaloid site interacting agents, colchicine site binders. This brief final contribution to this volume will focus only on the newly identified products for which active pharmaceutical development has been reported on during the last three years.
Keywords: Cryptophycines, Epothilones, Eleutherobines, vinflunine
Current Pharmaceutical Design
Title: Epilogue
Volume: 7 Issue: 13
Author(s): Jacques Fahy and Bridget T. Hill
Affiliation:
Keywords: Cryptophycines, Epothilones, Eleutherobines, vinflunine
Abstract: Besides the many recognised compounds described and detailed in the present issue including the Vinca alkaloids, the taxanes, certain cryptophycines, epothilones and eleutherobines, several new products interacting with tubulin are identified regularly in the literature. These products may have been isolated from natural sources (plants, marine organisms, bacteria), but also more recently combinatorial, or at least automatised chemistry, has provided new families of small molecules, which on occasions have been found by High Throughput Screening directed against tubulin as a specific target. A recent review has listed more than one hundred of such derivatives [1]. Certain of these are in an advanced stage of pharmaceutical development, as reviewed by Li et al. [2] and von Angerer [3]. From a mechanistic point of view, these newer products may be classified into one of three main families, although exceptions to this rule are now also being reported on. microtubule stabilising compounds, Vinca alkaloid site interacting agents, colchicine site binders. This brief final contribution to this volume will focus only on the newly identified products for which active pharmaceutical development has been reported on during the last three years.
Export Options
About this article
Cite this article as:
Fahy Jacques and Hill T. Bridget, Epilogue, Current Pharmaceutical Design 2001; 7 (13) . https://dx.doi.org/10.2174/1381612013397447
DOI https://dx.doi.org/10.2174/1381612013397447 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inhibitors of HDACs - Effective Drugs Against Cancer?
Current Cancer Drug Targets Decreasing the Metastatic Potential in Cancers - Targeting the Heparan Sulfate Proteoglycans
Current Drug Targets Pleiotropic Actions of PPARg Activators Thiazolidinediones in Cardiovascular Diseases
Current Pharmaceutical Design Amino Acid Degrading Enzymes and their Application in Cancer Therapy
Current Medicinal Chemistry Disorders of Mechanisms of Calcium Metabolism Control as Potential Risk Factors of Prostate Cancer
Current Medicinal Chemistry Advances of Paclitaxel Formulations Based on Nanosystem Delivery Technology
Mini-Reviews in Medicinal Chemistry Antisense Oligodeoxynucleotide Therapy for Prostate Cancer Targeting Antiapoptotic Genes Involved in the Mechanism Mediating Progression to Androgen Independence
Current Signal Transduction Therapy Antiproliferative Activities on Renal, Prostate and Melanoma Cancer Cell Lines of Sarcopoterium spinosum Aerial Parts and its Major Constituent Tormentic Acid
Anti-Cancer Agents in Medicinal Chemistry Tissue Distribution and Pharmacodynamics: A Complicated Relationship
Current Drug Metabolism Natural Compounds for Carcinoma Therapy by Wingless Signaling Pathway Down-regulation
Current Bioactive Compounds An Update on Poly(ADP-ribose) Polymerase I-A Brief Review
Mini-Reviews in Medicinal Chemistry Interleukin-6 Trans-Signaling and Colonic Cancer Associated with Inflammatory Bowel Disease
Current Pharmaceutical Design ADR in Journals: Are They Translated into Regulatory Frameworks?
Current Drug Safety Imiquimod 5% Cream Use in Dermatology, Side Effects and Recent Patents
Recent Patents on Inflammation & Allergy Drug Discovery Respiratory Stem Cells and Progenitors: Overview, Derivation, Differentiation, Carcinogenesis, Regeneration and Therapeutic Application
Current Stem Cell Research & Therapy A Mild and Convenient Semi-Synthesis of Docetaxel from 10-Deacetyl Baccatin III
Letters in Organic Chemistry 2-((1H-1,2,3-triazol-1-yl)methyl)-3-phenylquinazolin-4(3H)-ones: Design, Synthesis and Evaluation as Anti-cancer Agents
Current Bioactive Compounds Biotherapy for Autoimmune Liver Diseases
Current Pharmaceutical Biotechnology Pharmaco-Therapeutic Challenges in Cancer Biology with Focus on the Immune- System Related Risk Factors
Current Pharmaceutical Design Epigenetics of Triple-Negative Breast Cancer via Natural Compounds
Current Medicinal Chemistry